Bristol-Myers Squibb Company (BMY)

Over the past six months, several events have impacted Bristol Myers Squibb Co. (BMY) stock price. On October 1, 2025, the stock jumped 5.5% after the FDA granted Fast Track Designation to its Alzheimer's drug, BMS-986446. Around August 2025, the stock experienced a 4.2% drop following the company's decision to lower its full-year earnings forecast for 2025. Between October 7, 2024, and October 3, 2025, BMY's share price declined by 14.95%, and over the last six months, the stock has decreased by 20.01%.

There is no explicit information indicating significant demand seasonality for Bristol Myers Squibb Co. (BMY) products and services in the provided search results. Pharmaceutical product demand is generally less seasonal than consumer goods. Analysts anticipate a revenue decline of 5.8% over the next 12 months, suggesting demand challenges rather than seasonality.

Bristol Myers Squibb Co. (BMY) is a multinational biopharmaceutical company involved in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products, operating within the Healthcare sector. Its primary therapeutic areas include oncology, hematology, immunology, cardiovascular, and neuroscience. Key products include Apixaban (Eliquis) for atrial fibrillation, Nivolumab (Opdivo) for cancer, Lenalidomide (Revlimid) for multiple myeloma, Abatacept (Orencia) for autoimmune diseases, Pomalidomide (Pomalyst/Imnovid) for multiple myeloma and Kaposi sarcoma, Ipilimumab (Yervoy) for cancer, Luspatercept (Reblozyl) for anemia, and Cobenfy for schizophrenia.

Bristol Myers Squibb is headquartered in Princeton, New Jersey, with corporate headquarters in Lawrenceville, New Jersey. Approximately 70% to 71% of its revenues are generated from the United States. Its R&D hubs are located in Central New Jersey, the San Francisco Bay Area, and Cambridge, Massachusetts, with other R&D sites in Seville, Braine-l'Alleud, Tokyo, Hyderabad, Bangalore, and Wirral. Manufacturing sites are located in the U.S., Puerto Rico, Switzerland, Ireland, the Netherlands, France, Italy, England, Shanghai, and Aichi.

Historically, Bristol Myers Squibb has faced legal challenges that have impacted its reputation, including issues with the SEC and FDA, accusations of deceptive advertising campaigns, and litigation related to certain drugs. Notable past instances include a $2.1 million penalty fine in 2009 and a payment of over $515 million in 2007. In the past year, the company has focused on strengthening its pipeline through acquisitions and strategic collaborations, and on advancing its research.

Bristol Myers Squibb Co. (BMY) has a high level of institutional ownership, ranging from 76.41% to 80.78%. Major institutional shareholders include Vanguard Group Inc., BlackRock, Inc., JPMorgan Chase & Co, State Street Corp, Charles Schwab Investment Management Inc, and Capital International Investors. Individual insider ownership is minimal, reported between 0.09% and 0.32%.